We therefore hypothesized that, as observed in many cancers, HDAC6 is overexpressed in PAH contributing to proliferation and resistance to apoptosis of PASMCs and that selective HDAC6 inhibition may represent a promising novel approach for the treatment of PAH. Here, HDAC6 is linked to pulmonary arterial hypertension.